Honest Verdict, No Sponsored Posts - just what we'd actually keep.
PickSuperb

Better U Cost and Regulation Review: What At-Home Ketamine Really Costs

Better U Cost and Regulation Review: What At-Home Ketamine Really Costs
A · · 14 min read

Some links in this article are affiliate links. If you buy through them we may earn a commission, at no extra cost to you.

This review is about money and regulation, not medicine. Nothing here is medical advice, and nothing in it should be used to start, stop or change any treatment; those decisions belong with a qualified clinician who knows your history. What we can do is lay out two things Better U's marketing does not put front and centre: what its programs actually cost once the required extras are included, and the fact that the single federal permission allowing at-home ketamine to reach anyone's door carries an expiry date with no announced replacement.

Status note: everything below reflects the public record as of mid-November 2026. The regulatory position in particular is time-sensitive and has been extended at the last minute before, so verify the current rule before acting on anything in this section.

PickSuperb Verdict Box

Category

Verdict

PickSuperb Score

5.0 / 10

Best For

Readers researching cost and regulatory risk before discussing options with a qualified clinician, not as a basis for a treatment decision

Starting Price

$500 for 5 sessions up to $2,076 for the 27-session program; peer support, continued care and coaching are priced separately

Standout Feature

Better U's published safety information is unusually detailed for this sector, including an explicit warning that combining ketamine with benzodiazepines or other sedatives can cause coma or death

Biggest Catch

The DEA telemedicine flexibility that permits prescribing controlled substances without a prior in-person exam was set to expire 31 December 2026, and as of mid-November 2026 no further extension had been issued and the permanent replacement rule remained unpublished

Reputation Note

Ketamine has no FDA approval for any psychiatric use, so all such prescribing is off-label; a wrongful-death lawsuit filed in March 2026 remains pending and undecided, and every large study of at-home ketamine we found was conducted or funded by a company selling the treatment

Better U is among the cheapest routes to supervised-at-a-distance ketamine therapy in the US, and its published safety documentation is more thorough than much of its sector. The honest catch is that the price is low partly because no clinician is present and no insurer is involved, the evidence base is almost entirely vendor-generated, and the legal permission underpinning the whole model has an expiry date.

The Regulatory Cliff: The Most Important Fact in This Review

At-home ketamine telehealth exists because of a temporary rule. Under the Ryan Haight Act, prescribing a controlled substance normally requires a prior in-person medical evaluation. A COVID-era flexibility waived that requirement, and it has been extended four times. The fourth extension, published 31 December 2025, runs from 1 January 2026 through 31 December 2026.

As of mid-November 2026, we could find no fifth extension and no final permanent rule. A coalition of health care and patient organisations formally petitioned the DEA and the White House budget office on 2 November 2026 for an extension through at least the end of 2027, noting 59 days remained and reporting no response. The permanent replacement, a special registration framework proposed in January 2025 that drew more than 6,400 comments, was sent to the White House budget office on 25 August 2026 and had not been published.

What that means in practice, stated carefully: if nothing is issued before 1 January 2027, the pre-pandemic in-person examination requirement returns, and a clinician who has never examined a patient in person could not lawfully issue a new telemedicine prescription for a controlled substance. Prescriptions already validly issued are not retroactively void, so the practical effect would be that new prescriptions and refills stop rather than that existing medication is recalled. The fourth extension contains no continuity-of-care provision, no grandfathering and no transition period for patients mid-treatment. Ketamine telehealth also does not benefit from either of the two permanent telemedicine rules the DEA did finalise, which cover buprenorphine for opioid use disorder and continuity of care for veterans only.

One important caveat against over-reading this. The pattern in previous years has been a last-minute extension: in 2025, the DEA signalled the forthcoming extension in November and published it on 30 December, one day before expiry. A late-December extension in 2026 remains entirely possible, and legal commentators note the agency could also issue an interim extension before finalising the permanent rule. Anyone affected should check the current rule rather than relying on this or any other article.

We found no public statement from Better U about the deadline. Its own August 2026 release on eligibility and safety does not mention the DEA at all. Trade-press analysis of the sector has been blunter, with one pharmaceutical industry publication concluding in January 2026 that telemedicine-only providers may be left without a viable compliant model if no permanent framework is set.

What It Actually Costs

Better U's published program pricing is genuinely among the lowest in its category.

Program

Sessions

Per session

Total

Introduction

5

$100

$500

Transformation

9

$88

$792

Introduction (3-month)

15 + 3 integration

$90

$1,350

Transformation (3-month)

27 + 6 integration

$76

$2,076

Each includes a ketamine consultation, one virtual clinical appointment with a licensed clinician, preparation with a certified integration guide, portal access, integration coaching, a starter kit, home-delivered medication and secure texting with the care team.

The Costs the Headline Price Does Not Include

This is the part worth knowing before comparing Better U to anything else. A sober adult must be physically present for every dosing session. If you do not have someone, Better U sells virtual peer support with a registered nurse at $59 per session. On the 27-session program, that is a potential $1,593 addition, roughly 77 percent on top of the $2,076 headline price.

Continued care is a separate purchase: five sessions for $395 or nine for $711, offered as a one-time payment or a monthly subscription whose price, billing frequency and cancellation terms Better U does not publish. Integrative coaching runs $299 a month. Refunds are available only if you pay and are then screened out as unsuitable; once treatment starts, there are none. Financing is offered from around $45 a month through a third-party provider, and we could not find a published APR anywhere, which is a meaningful omission on a financed health purchase. Better U's own cost page also carries two conflicting sets of financing figures simultaneously and contradicts itself on which packages qualify, which is a transparency problem in its own right.

Insurance Does Not Cover This, and the Reason Is Structural

Better U states plainly that at-home ketamine treatment is not covered by insurance, that it is not in-network with commercial insurance, and that it is not enrolled with Medicare or Medicaid for these services. It accepts HSA and FSA funds and will provide a superbill for possible out-of-network reimbursement of the clinical consultation only. The same is true of its competitors. The structural reason is that the FDA has approved no ketamine product for any psychiatric indication, and the medication shipped is a compounded preparation, which by definition is not an FDA-approved finished drug product. Payers do not reimburse it.

The Cost Comparison, and Why It Is Not Like-for-Like

Option

Typical cost

Insurance

Supervision during dosing

Better U

$500-$2,076 per program; +$59/session if peer support is bought

None

No clinician present; lay peer or paid nurse by video

Mindbloom

$1,290 for 6 sessions ($215/session)

None

Peer monitor

Joyous

$129/month, low-dose daily model

None

Remote check-ins

In-clinic IV ketamine

~$300-$690 per infusion

Generally not covered

Full clinical monitoring

Spravato (esketamine)

~$882-$1,319 cash per dose, plus facility fee

Yes, FDA-approved and routinely covered

Certified setting, 2+ hours observation

The headline contrast is striking: Better U's entire 27-session, three-month program costs less than two cash-price doses of Spravato. But the comparison is not like-for-like and we are not going to present it as one. Spravato's price buys an FDA-approved product given under a risk-management programme with two hours of clinical observation, and because it is covered, most patients pay a copay rather than the list price. Better U's price is what the patient actually pays, and it buys an off-label compounded medication self-administered with no clinician present. The cheap option is cheap partly because the supervision has been removed from it. That is the honest framing of the cost gap.

Pros and Cons

Pros

•      Among the lowest published per-session prices in at-home ketamine therapy, at $76-$100 per session depending on program

•      Published safety information is unusually detailed for the sector, including an explicit warning that combining ketamine with alcohol, opioids, benzodiazepines or other sedatives can cause profound sedation, breathing suppression, coma or death

•      Lists specific contraindications in detail and requires a sober adult to be present, stating plainly that a support person is not a medical professional and cannot replace clinical monitoring

•      Emergency guidance is direct, instructing patients to call emergency services rather than wait for a portal response, and stating the platform is not emergency or inpatient psychiatric care

Cons

•      The DEA flexibility the whole model depends on was due to expire 31 December 2026, with no extension issued and no permanent rule published as of mid-November 2026

•      Required peer support at $59/session can add up to roughly 77% on top of the largest program's headline price

•      No insurance coverage of any kind, no refunds once treatment begins, and no published APR on the financing offered

•      Every large study of at-home ketamine we located was conducted or funded by a company selling the treatment, with no randomised placebo-controlled trial of unsupervised at-home use

•      A wrongful-death lawsuit filed in March 2026 remains pending with no reported developments

What the Evidence Actually Shows, and What It Doesn't

There is real published research here, and it reports substantial improvements. A 2022 study of 1,247 patients found roughly 63 percent achieved at least 50 percent improvement in depression scores over four weeks. A larger 2026 retrospective study of 3,041 patients across 38 states reported comparable improvements in depression, anxiety and PTSD measures after about six sessions.

The limitation is the same in every case and it is fundamental: these are open-label or retrospective studies with no control arm, and they were conducted on the platforms of the companies selling the treatment, with company employees among the authors. There is, as far as we could find, no randomised placebo-controlled trial of unsupervised at-home sublingual ketamine for depression. Ketamine is strongly placebo-sensitive, and its dissociative effects make blinding difficult, which makes the absence of control arms more consequential here than it would be for most drugs. The 2026 study's own authors list the lack of a comparison arm, higher attrition than a trial, a self-selected sample and an inability to separate the drug's effect from the clinical support surrounding it among their limitations. That study also recorded three serious adverse events among 3,041 patients, roughly 0.08 percent: one psychotic episode judged likely related to the medication, and two patients who died by suicide during treatment, with attribution undetermined.

What Regulators and Professional Bodies Say

The FDA issued a warning in October 2023 about compounded ketamine products, noting that ketamine is not approved for any psychiatric disorder, that safe and effective dosing for such uses has not been established, and that without an onsite provider to monitor for sedation and dissociation, patients may be at risk. It cited an adverse event report of respiratory depression in a patient who took compounded oral ketamine outside a healthcare setting.

A June 2024 position paper from the professional society for ketamine practitioners opposes unsupervised at-home subcutaneous ketamine outright, saying there is not adequate evidence to support the practice as safe and appropriate. On oral at-home ketamine it is more permissive but still stricter than any telehealth platform's protocol, recommending that patients first have supervised in-office treatment without complications and that the initial consultation and risk assessment be done in person. In June 2026 the American Society of Anesthesiologists called for policymakers to address at-home ketamine delivery and the lack of physician oversight, citing breathing problems, sudden blood pressure and heart rate changes, and misuse. It referenced the death of a 41-year-old New York woman after receiving at-home ketamine through a telehealth company who had reported taking a benzodiazepine, which the FDA warns can cause fatal breathing problems.

A 2026 article in a psychiatric journal, which takes a wrongful-death lawsuit against a telehealth ketamine provider as its starting point, makes a structural argument worth noting: accountability and liability fall heavily on individual prescribing clinicians who have little control over the platform's business model. That connects directly to how Better U describes itself, as a telehealth technology and administrative platform that does not practise medicine, with clinical services provided by independently owned medical practices and prescriptions fulfilled by third-party pharmacies.

Better U's Published Safety Guardrails

Credit where it is due: Better U's safety information page is more detailed than much of this sector, and it addresses the drug-interaction question directly. It warns explicitly that combining ketamine with alcohol, opioids, benzodiazepines, sleep medicines or other sedatives can cause profound sedation, breathing suppression, coma or death, and instructs patients to get an individualised plan before a session rather than adjusting prescriptions themselves. It lists detailed contraindications spanning cardiac, respiratory, neurological, hepatic, renal and psychiatric conditions, substance use, pregnancy and age. It requires a sober adult physically present, states that a support person cannot replace clinical monitoring, requires blood pressure logging before each session, and restricts driving and sole care of dependents.

What is not there is in-session clinical monitoring. Across the company's own materials, the only measurement taken is a self-recorded blood pressure reading before dosing, with a lay peer or a paid nurse on video present during. One independent reviewer described a 25-minute initial psychiatric consultation and a 30-minute group preparation call with roughly ten participants, and found the initial consultation rushed.

One question we specifically could not answer: whether that detailed safety language, including the benzodiazepine warning, predates the March 2026 lawsuit or was added or strengthened afterwards. Better U has made no public statement announcing protocol changes in response to the litigation. We are not asserting that the company tightened its screening after the lawsuit, and we are not asserting that it did not. The defensible statement is simply that as of late 2026 its published safety information carries that warning, and we could not establish when it appeared.

The Sector in 2026

The competitive field includes Mindbloom, the largest, operating in 38 states and offering at-home subcutaneous injection alongside sublingual tablets; Joyous, with a low-dose daily model at $129 a month; and Better U in 30 states, plus several smaller operators. There have been casualties: one well-funded provider hit financial distress and was acquired in late 2023, and a tele-ketamine prescriber in South Carolina had its DEA registration suspended in 2023 over prescribing without adequate examinations.

State-level regulation is moving faster than federal. The Texas Medical Board has proposed rules that would prohibit ketamine being administered outside a registered clinic and prescribed for home use, with detailed monitoring requirements. As of mid-November 2026 those rules remained proposed with no adoption date. There is an important scope limit worth getting right, though: as drafted the Texas rules cover parenteral ketamine, meaning intravenous, subcutaneous and intramuscular routes. Oral and sublingual are not mentioned. So as written, they would end at-home subcutaneous ketamine but would not reach Better U's sublingual format. Bills to strengthen patient protections have reportedly been introduced in several other states, though we could not verify their numbers or status.

On litigation, we found no reporting of developments in the wrongful-death case since the March 2026 filing: no answer, no motion practice, no settlement, no dismissal. It should be treated as pending and undecided, and no outcome should be inferred.

Who This Review Is and Isn't For

Useful For: Understanding Cost and Regulatory Risk

If you are trying to work out what at-home ketamine therapy would actually cost you including the extras, how that compares to clinic-based or FDA-approved alternatives, and what regulatory risk sits over the delivery model, the figures above are the honest picture.

Not a Basis For: A Treatment Decision

Whether ketamine therapy of any form is appropriate for a particular person is a clinical question involving their history, current medications and contraindications. That conversation belongs with a qualified clinician who can review all of it, and nothing in this review substitutes for it.

Pricing and Where to Find It

Better U publishes its program pricing on its own site, which is more than several competitors do. When comparing, add the peer-support cost if you would need it, treat continued care as a separate purchase, and ask for the financing APR in writing before accepting any payment plan.

Frequently Asked Questions

Is at-home ketamine therapy FDA-approved?

No. Ketamine has no FDA approval for any psychiatric indication, so all such prescribing is off-label, and the medication supplied is a compounded preparation rather than an FDA-approved finished product. Spravato, a related but different medication, is FDA-approved but must be given in a certified healthcare setting with at least two hours of observation.

What happens to at-home ketamine after 31 December 2026?

As of mid-November 2026 the DEA flexibility permitting prescribing without a prior in-person exam was due to expire that date, with no further extension issued and the permanent replacement rule still unpublished. If nothing is issued, the in-person examination requirement returns. A last-minute extension has happened in previous years, so check the current rule rather than relying on any article.

Does insurance cover Better U?

No. Better U states it is not in-network with commercial insurance and not enrolled with Medicare or Medicaid for these services. It accepts HSA and FSA funds and provides a superbill for possible out-of-network reimbursement of the clinical consultation only.

What does Better U actually cost in total?

Programs run from $500 for five sessions to $2,076 for 27. Beyond that, virtual peer support is $59 per session where needed, continued care is $395 for five sessions or $711 for nine, and coaching is $299 a month. There are no refunds once treatment begins.

How strong is the evidence for at-home ketamine?

Weaker than the headline improvement figures suggest. The large published studies report substantial improvements but are open-label or retrospective with no control arm, and were conducted or funded by companies selling the treatment. We found no randomised placebo-controlled trial of unsupervised at-home use.

PickSuperb Scorecard

Category

Score

Price Transparency on the Headline Program

6.5 / 10

Disclosure of Add-On and Total Costs

3.5 / 10

Published Safety Documentation

7.0 / 10

Regulatory Durability of the Model

2.5 / 10

Overall PickSuperb Score

5.0 / 10

Final Verdict

The cheapest at-home ketamine program in the US is cheap for two specific reasons: no clinician is present during dosing, and no insurer is involved. Better U deserves real credit for publishing detailed safety information, including a direct warning about the sedative interaction at the centre of the litigation against it, and for listing its prices openly. But the honest picture is that the headline price can grow by most of itself again once required peer support is added, the financing carries no published APR, the evidence base is almost entirely vendor-generated, and the federal permission that lets any of this reach a patient's door was set to expire at the end of 2026 with no announced replacement. Anyone weighing this should treat the cost figures above as the starting point, confirm the current regulatory position, and have the clinical conversation with a qualified professional rather than with a website. For another honest look at a wellness device brand whose marketing claims outpace its published evidence, see our Therabody massage gun review.

If you or someone you know is struggling with depression or thoughts of suicide, support is available: in the US you can call or text 988 to reach the Suicide and Crisis Lifeline. This article is for information only and is not a substitute for professional medical advice, diagnosis or treatment.

Share:
A

0 Comments

No comments yet - be the first to share your thoughts.

Leave a comment

Your email won't be published.